UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 87.

Weiler, Stefan; Kullak-Ublick, G A (2017). Pharmacovigilance: von «primum non nocere» zu «qua nocent docent». Swiss Medical Forum, 17(28-29):590-593.

Visentin, M; van Rosmalen, B V; Hiller, C; Bieze, M; Hofstetter, L; Verheij, J; Kullak-Ublick, G A; Koepsell, H; Phoa, S S; Tamai, I; Bennink, R J; van Gulik, T M; Stieger, B (2017). Impact of organic cation transporters (OCT-SLC22A) on differential diagnosis of intrahepatic lesions. Drug Metabolism and Disposition, 45(2):166-173.

Brown, Lisa; Kullak-Ublick, G A (2017). Risiko / Benefit-Betrachtung der SGLT-2 Inhibitoren. info@herz+gefäss, (1):17-19.

Russmann, S; Kullak-Ublick, G A; Weiler, S; Stoller, R; Egbring, M (2016). Arzneimittelsicherheit. In: Siepmann, T; Kirch, W; Kullak-Ublick, G A. Arzneimitteltherapie : Wirksamkeit - Sicherheit - Praktische Anwendung. Stuttgart: George Thieme Verlag, 71-99.

Arzneimitteltherapie. Edited by: Siepmann, T; Kirch, W; Kullak-Ublick, G A (2016). Stuttgart, New York: Georg Thieme Verlag.

Weiler, Stefan; Taegtmeyer, Anne B; Müller, Sabine; Rollason, Victoria; Livio, Francoise; Ceschi, Alessandro; Kullak-Ublick, G A (2016). Ausgewählte Fälle aus den regionalen Pharmacovigilance-Zentren. Swiss Medical Forum, 16(37):757-763.

Weiler, Stefan; Russmann, Stefan; Stoller, Rudolf (2016). Pharmakovigilanz. In: Kullak-Ublick, G A; Siepmann, T; Kirch, Wilhelm. Arzneimitteltherapie : Wirksamkeit - Sicherheit - Praktische Anwendung. Stuttgart: Georg Thieme Verlag, 84-91.

Weiler, Stefan; Stoller, Rudolf; Russmann, Stefan (2016). Unerwünschte Arzneimittelwirkungen (UAW). In: Kullak-Ublick, G A; Siepmann, T; Kirch, Wilhelm. Arzneimitteltherapie : Wirksamkeit - Sicherheit - Praktische Anwendung. Stuttgart: Georg Thieme Verlag, 76-81.

Dahmke, H; Kullak-Ublick, G A (2016). Update Diuretika. Der Informierte Arzt, 6(9):17-20.

Weiler, S; Kullak-Ublick, G A; Jetter, A (2015). Klinisch relevante unerwünschte Arzneimittelinteraktionen: Tipps für die Praxis. Swiss Medical Forum, 15(7):152-156.

Dahmke, H; Kupferschmidt, H; Kullak-Ublick, G A; Weiler, S (2015). Nalmefen und Opioid-Entzugssyndrom: systematische Analyse der globalen Pharmacovigilance Datenbank. Praxis, 2015(104):1129-1134.

Stieger, B; Kullak-Ublick, G A (2015). Transporters in the liver. In: Urban, L; Patel, V F; Vaz, R J. Antitargets and Drug Safety. KGaA, Weinheim: Wiley-VCH Verlag GmbH & Co., 159-171.

Meli, Marianne; Rauber-Lüthy, Christine; Kupferschmidt, Hugo; Kullak-Ublick, G A; Ceschi, A. Atypical antipsychotic poisoning in young children: a multicentre analysis of poisons centres data. 2014, University of Zurich, Faculty of Medicine.

Eloranta, J J; Stieger, B; Kullak-Ublick, G A (2014). Bile salt transporters. In: You, G; Morris, M E. Drug Transporters: Molecular Characterization and Role in Drug Disposition. Hoboken, New Jersey: Wiley Series in Drug Discovery and Development, John Wiley & Sons Inc.., 127-139.

Aellig, N; Krüger, B; Schwartz, T; Kullak-Ublick, G A; Schmid-Grendelmeier, P; Russmann, S (2014). Chlorhexidin-Allergie. Swiss Medical Forum, 14(15):321-322.

Russmann, S; Kullak-Ublick, G A (2012). Beurteilung und Meldung medikamentöser Leberschäden. Vigilance-News, (10):9-14.

Russmann, S; Kullak-Ublick, G A (2012). Arzneimittelsicherheit. In: Kullak-Ublick, G A; Siepmann, T; Kirch, W. Arzneimitteltherapie: Wirksamkeit - Sicherheit - Praktische Anwendung. Stuttgart: Thieme, 27-31.

Arzneimitteltherapie: Wirksamkeit - Sicherheit - Praktische Anwendung. Edited by: Kullak-Ublick, G A; Siepmann, T; Kirch, W (2012). Stuttgart: Thieme.

Russmann, S (2012). Arzneimittelsicherheit in klinischen Studien. In: Kullak-Ublick, G A; Siepmann, T; Kirch, W. Arzneimitteltherapie: Wirksamkeit - Sicherheit - Praktische Anwendung. Stuttgart: Thieme, 35-38.

Müller, E A; Krattinger, R (2012). Arzneitherapie gastrointestinaler Erkrankungen. In: Kullak-Ublick, G A; Siepmann, T; Kirch, W. Arzneimitteltherapie: Wirksamkeit - Sicherheit - Praktische Anwendung. Stuttgart: Thieme, 104-123.

Taegtmeyer, A B; Kullak-Ublick, G A; Widmer, N; Falk, V; Jetter, A (2012). Clinical Usefulness of Electronic Drug-Drug Interaction Checking in the Care of Cardiovascular Surgery Inpatients. Cardiology, 123(4):219-222.

Egbring, M; Russmann, S; Kullak-Ublick, G A (2012). Clinical decision support systems. In: Kullak-Ublick, G A; Siepmann, T; Kirch, W. Arzneimitteltherapie: Wirksamkeit - Sicherheit - Praktische Anwendung. Stuttgart: Thieme, 49-52.

Zorina, O I; Haueis, P; Semmler, A; Marti, I; Gonzenbach, R R; Guzek, M; Kullak-Ublick, G A; Weller, M; Russmann, S (2012). Comparative evaluation of the drug interaction screening programs MediQ and ID PHARMA CHECK in neurological inpatients. Pharmacoepidemiology and Drug Safety, 21(8):872-880.

Haueis, P; Russmann, S; Zorina, O I; Grohmann, R; Kullak-Ublick, G A; Jaquenoud Sirot, E; Russmann, H (2012). Coprescription of levodopa with antipsychotics in a population of 84 596 psychiatric inpatients from 1994 to 2008. Pharmacopsychiatry, 45(04):127-132.

Scharl, M; Mwinyi, J; Fischbeck, A; Leucht, K; Eloranta, J J; Arikkat, J; Pesch, T; Kellermeier, S; Mair, A; Kullak-Ublick, G A; Truninger, K; Noreen, F; Regula, J; Gaj, P; Pittet, V; Mueller, C; Hofmann, C; Fried, M; McCole, D F; Rogler, G (2012). Crohn's disease-associated polymorphism within the PTPN2 gene affects muramyl-dipeptide-induced cytokine secretion and autophagy. Inflammatory Bowel Diseases, 18(5):900-912.

Hammann, F; Hruz, P; Kullak-Ublick, G A; Vavricka, S R; Beglinger, C; Drewe, J; Gutmann, H (2012). Determination of the Single Nucleotide Polymorphisms C3435 and G2677T in MDR1 and C421A in BCRP in blood samples of patients with inflammatory bowel disease and healthy controls in the swiss population. Metabolomics, 2:104.

Taegtmeyer, A B; Curkovic, I; Corti, N; Rosen, C; Egbring, M; Russmann, S; Gantenbein, A R; Weller, M; Kullak-Ublick, G A (2012). Drug-related problems and factors influencing acceptance of clinical pharmacologists` alerts in a large cohort of neurology inpatients. Swiss Medical Weekly, 142:w13615.

Corti, N (2012). Intensivmedizinische Arzneitherapie. In: Kullak-Ublick, G A; Siepmann, T; Kirch, W. Arzneimitteltherapie: Wirksamkeit - Sicherheit - Praktische Anwendung. Stuttgart: Thieme, 359-371.

Russmann, S (2012). Pharmakoepidemiologie. In: Kullak-Ublick, G A; Siepmann, T; Kirch, W. Arzneimitteltherapie: Wirksamkeit - Sicherheit - Praktische Anwendung. Stuttgart: Thieme, 42-48.

Taegtmeyer, A B; Ceschi, A; Kullak-Ublick, G A; Jetter, A (2012). Pharmakogenetik in der Praxis: warum, wie, wann? - Teil 1. Swiss Medical Forum, 12(42):808-811.

Taegtmeyer, A B; Ceschi, A; Kullak-Ublick, G A; Jetter, A (2012). Pharmakogenetik in der Praxis: warum, wie, wann? - Teil 2. Swiss Medical Forum, 12(42):824-826.

Sift Carter, R; Russmann, S; Stoller, R (2012). Pharmakovigilanz. In: Kullak-Ublick, G A; Siepmann, T; Kirch, W. Arzneimitteltherapie: Wirksamkeit - Sicherheit - Praktische Anwendung. Stuttgart: Thieme, 38-41.

Egbring, M (2012). Pharmakoökonomie. In: Kullak-Ublick, G A; Siepmann, T; Kirch, W. Arzneimitteltherapie: Wirksamkeit - Sicherheit - Praktische Anwendung. Stuttgart: Thieme, 23-26.

Ma, L; Jüttner, M; Kullak-Ublick, G A; Eloranta, J J (2012). Regulation of the gene encoding the intestinal bile acid transporter ASBT by the caudal-type homeobox proteins CDX1 and CDX2. American Journal of Physiology. Gastrointestinal and Liver Physiology, 302(1):G123-33.

Curkovic, I; Kullak-Ublick, G A (2012). Schmerztherapie und Lokalanästhetika. In: Kullak-Ublick, G A; Siepmann, T; Kirch, W. Arzneimitteltherapie: Wirksamkeit - Sicherheit - Praktische Anwendung. Stuttgart: Thieme, 228-246.

Sift Carter, R; Stoller, R; Russmann, S (2012). Unerwünschte Arzneimittelwirkungen. In: Kullak-Ublick, G A; Siepmann, T; Kirch, W. Arzneimitteltherapie: Wirksamkeit - Sicherheit - Praktische Anwendung. Stuttgart: Thieme, 32-35.

Fuchs, J; Rauber-Lüthy, C; Kupferschmidt, H; Kupper, J; Kullak-Ublick, G A; Ceschi, A (2011). Acute plant poisoning: analysis of clinical features and circumstances of exposure. Clinical Toxicology, 49(7):671-680.

Eloranta, J J; Wenger, C; Mwinyi, J; Hiller, C; Gubler, C; Vavricka, S R; Fried, M; Kullak-Ublick, G A (2011). Association of a common vitamin D-binding protein polymorphism with inflammatory bowel disease. Pharmacogenetics and Genomics, 21(9):559-564.

Vavricka, B M P; Baumberger, P; Russmann, S; Kullak-Ublick, G A (2011). Diagnosis of melanoma under concomitant natalizumab therapy. Multiple Sclerosis, 17(2):255-256.

Taegtmeyer, A B; Müller, V; Kovari, H; Kullak-Ublick, G A; Corti, N (2011). Effect of continuous venovenous hemodiafiltration on darunavir and raltegravir exposure after administration via a gastroduodenal tube. AIDS, 25(10):1339-1341.

Taegtmeyer, A B; Curkovic, I; Rufibach, K; Corti, N; Battegay, E; Kullak-Ublick, G A (2011). Electronic prescribing increases uptake of clinical pharmacologists' recommendations in the hospital setting. British Journal of Clinical Pharmacology, 72(6):958-964.

Guzek, M; Zorina, O I; Semmler, A; Gonzenbach, R R; Huber, M; Kullak-Ublick, G A; Weller, M; Russmann, S (2011). Evaluation of drug interactions and dosing in 484 neurological inpatients using clinical decision support software and an extended operational interaction classification system (Zurich Interaction System). Pharmacoepidemiology and Drug Safety, 20(9):930-938.

Haueis, P; Greil, W; Huber, M; Grohmann, R; Kullak-Ublick, G A; Russmann, S (2011). Evaluation of drug interactions in a large sample of psychiatric inpatients: A data interface for mass analysis with clinical decision support software. Clinical Pharmacology and Therapeutics, 90(4):588-596.

Frölich, T; Zorina, O; Fontana, A O; Kullak-Ublick, G A; Vollenweider, A; Russmann, S (2011). Evaluation of medication safety in the discharge medication of 509 surgical inpatients using electronic prescription support software and an extended operational interaction classification. European Journal of Clinical Pharmacology, 67(12):1273-1282.

Hofer, K E; Trachsel, C; Rauber-Lüthy, C; Kupferschmidt, H; Kullak-Ublick, G A; Ceschi, A (2011). Moderate toxic effects following acute zonisamide overdose. Epilepsy & Behavior, 21(1):91-93.

de Graaf, W; Häusler, S; Heger, M; van Ginhoven, T M; van Cappellen, G; Bennink, R J; Kullak-Ublick, G A; Hesselmann, R; van Gulik, T M; Stieger, B (2011). Transporters involved in the hepatic uptake of (99m)Tc-mebrofenin and indocyanine green. Journal of Hepatology, 54(4):738-745.

Mwinyi, J; Wenger, C; Eloranta, J J; Kullak-Ublick, G A (2010). Glucocorticoid receptor gene haplotype structure and steroid therapy outcome in IBD patients. World Journal of Gastroenterology, 16(31):3888-3896.

Egbring, M; Kullak-Ublick, G A; Russmann, S (2010). Phynx: an open source software solution supporting data management and web-based patient-level data review for drug safety studies in the general practice research database and other health care databases. Pharmacoepidemiology and Drug Safety, 19(1):38-44.

Yilmaz, Z; Ceschi, A; Rauber-Lüthy, C; Sauer, O; Stedtler, U; Prasa, D; Seidel, C; Hackl, E; Hoffmann-Walbeck, P; Gerber-Zupan, G; Bauer, K; Kupferschmidt, H; Kullak-Ublick, G A; Wilks, M (2010). Escitalopram causes fewer seizures in human overdose than citalopram. Clinical Toxicology, 48(3):207-212.

Mwinyi, J; Kullak-Ublick, G A (2010). Hereditäre Defekte hepatobiliärer Transportproteine. Der Gastroenterologe, 5(1):39-48.

Non adherence - non response. Edited by: Kullak-Ublick, G A; Jetter, A (2010). Bern, CH: Hans Huber Verlag.

Jetter, A; Kullak-Ublick, G A (2010). Non adherence – non response. Therapeutische Umschau, 67(6):281-282.

Russmann, S; Jetter, A; Kullak-Ublick, G A (2010). Pharmacogenetics of drug-induced liver injury. Hepatology, 52(2):748-761.

Corti, N; Grimm, V; Kullak-Ublick, G A (2010). Polymedikation und Wechselwirkungen: Medikamente bei älteren Patienten richtig dosieren. Zahnarzt Praxis, (2):1-6.

Klein, K; Jungst, C; Mwinyi, J; Stieger, B; Krempler, F; Patsch, W; Eloranta, J J; Kullak-Ublick, G A (2010). The Human Organic Anion Transporter Genes OAT5 and OAT7 Are Transactivated by Hepatocyte Nuclear Factor-1{alpha} (HNF-1{alpha}). Molecular Pharmacology, 78(6):1079-1087.

Wojtal, K A; Eloranta, J J; Hruz, P; Gutmann, H; Drewe, J; Beglinger, C; Fried, M; Kullak-Ublick, G A; Vavricka, S R (2009). Changes in mRNA expression levels of solute carrier transporters in inflammatory bowel disease patients. Drug Metabolism and Disposition, 37(9):1871-1877.

Eloranta, J J; Hiller, C; Hausler, S; Stieger, B; Kullak-Ublick, G A (2009). Vitamin D3 and its nuclear receptor increase the expression and activity of the human proton-coupled folate transporter. Molecular Pharmacology, 76(5):1062-1071.

Kullak-Ublick, G A; Eloranta, J J (2009). Nuclear receptor regulation of bile acid transporters. In: Keppler, D; Beuers, U; Steihl, A; Trauner, M. Bile Acid Biology and Therapeutic Actions. Berlin: Springer, 111-114.

Klein, K; Kullak-Ublick, G A; Wagner, M; Trauner, M; Eloranta, J J (2009). Hepatocyte nuclear factor-4{alpha} and bile acids regulate human concentrative nucleoside transporter-1 gene expression. American Journal of Physiology. Gastrointestinal and Liver Physiology, 296(4):G936-G947.

Perger, L; Rentsch, K M; Kullak-Ublick, G A; Verotta, D; Fattinger, K (2009). Oral heroin in opioid-dependent patients: Pharmacokinetic comparison of immediate and extended release tablets. European Journal of Pharmaceutical Sciences, 36(4-5):421-432.

Stieger, B; Ismair, M G; Guyot, C; Synal-Hermanns, U; Kullak-Ublick, G A (2009). Canalicular microdomains and bile formation. In: Keppler, D; Beuers, U; Stiehl, A; Trauner, M. Bile Acid Biology and Therapeutic Actions. Dordrecht, NL: Springer, 31-35.

Huber, M; Kullak-Ublick, G A; Kirch, W (2009). Drug information for patients - an update of long-term results: type of enquiries and patient characteristics. Pharmacoepidemiology and Drug Safety, 18(2):111-119.

Beuers, U; Kullak-Ublick, G A; Pusl, T; Rauws, E R; Rust, C (2009). Medical treatment of primary sclerosing cholangitis: A role for novel bile acids and other (post-)transcriptional modulators? Clinical Reviews in Allergy and Immunology, 36(1):52-61.

Huber, M; Kullak-Ublick, G A; Kirch, W (2009). 6 Jahre Erfahrungen mit einem Arzneimittelberatungsdienst für Patienten. Medizinische Klinik, 104(3):220-224.

Russmann, S; Kullak-Ublick, G A; Grattagliano, I (2009). Current concepts of mechanisms in drug-induced hepatotoxicity. Current Medicinal Chemistry, 16(23):3041-3053.

Russmann, S; Szeless, T; Bock, A; Kullak-Ublick, G A (2009). Natriumphosphat enthaltende Darmreinigungsmittel – eine Gefahr für die Niere? Swiss Medical Forum, 9(18):336-339.

Zaïr, Z M; Eloranta, J J; Stieger, B; Kullak-Ublick, G A (2008). Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney. Pharmacogenomics, 9(5):597-624.

Meier, Y; Zodan, T; Lang, C; Zimmermann, R; Kullak-Ublick, G A; Meier, P J; Stieger, B; Pauli-Magnus, C (2008). Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of the 1331T>C polymorphism in the bile salt export pump. World Journal of Gastroenterology, 14(1):38-45.

Darimont, J; Kullak-Ublick, G A (2008). Erkrankungen des Bilirubinstoffwechsels und der Gallensäurebildung. In: Riemann, J F; Mössner, J. Gastroenterologie: Das Referenzwerk für Klinik und Praxis, Volume 2: Leber, Galle, Pankreas. Stuttgart, New York: Thieme, 1680-1686.

Huber, M; Kullak-Ublick, G A (2008). Generika: Worauf sollte man beim Umstellen achten? Ars Medici, 16:1-5.

Huber, M; Kullak-Ublick, G A (2008). Generika: Worauf sollte man beim Umstellen achten? The Medical Journal (TMJ), 3:23-26.

Eloranta, J J; Kullak-Ublick, G A (2008). The role of FXR in disorders of bile acid homeostasis. Physiology, 23:286-295.

Jüngst, C; Sreejayan, N; Zündt, B; Müller, I; Spelsberg, F W; Hüttl, T P; Kullak-Ublick, G A; del Pozo, R; Jüngst, D; von Ritter, C (2008). Ursodeoxycholic acid reduces lipid peroxidation and mucin secretagogue activity in gallbladder bile of patients with cholesterol gallstones. European Journal of Clinical Investigation, 38(9):634-639.

Georgiev, P; Navarini, A A; Eloranta, J J; Lang, K S; Kullak-Ublick, G A; Nocito, A; Dahm, F; Jochum, W; Graf, R; Clavien, P-A (2007). Cholestasis protects the liver from ischaemic injury and post-ischaemic inflammation in the mouse. Gut, 56(1):121-128.

Eloranta, J J; Kullak-Ublick, G A (2007). Enterohepatic bile acid transporters and transcriptional control of their expression. In: Young, G; Morris, M E. Drug Transporters: Molecular characterization and role in drug disposition. Hoboken: Wiley and Sons, 201-221.

Jüngst, C; Kullak-Ublick, G A (2007). Gallensteine – eine Leberkrankheit? Teil 1. Pathogenese. Schweiz Med Forum, 7(33):668-673.

Jüngst, C; Kullak-Ublick, G A (2007). Gallensteine – eine Leberkrankheit? Teil 2.: Klinik und Therapie. Swiss Medical Forum, 7:692-695.

Corti, N; Kullak-Ublick, G A (2007). Pharmacogenetics. In: Blum, H E; Cox, D W; Häussinger, D; Janssen, P L M; Kullak-Ublick, G A. Genetics in Liver Diseases. Dordrecht (NL): Springer, 3-7.

Eloranta, J J; Kullak-Ublick, G A (2007). Regulation of hepatic and intestinal bile acid transport by FXR-controlled pathways. In: Keppler, D; Beuers, U; Leuschner, U; Stiehl, A; Trauner, M; Paumgartner, G. Bile Acids: Biological Actions and Clinical Relevance. Dordrecht (NL): Springer, 115-120.

Frei, P; Fried, M; Hungerbuhler, V; Rammert, C; Rousson, V; Kullak-Ublick, G A (2006). Analysis of risk factors for low bone mineral density in inflammatory bowel disease. Digestion, 73(1):40-46.

Bauerfeind, P; Müllhaupt, B; Schöfl, R; Rösch, T; Schwizer, W; Wirth, H P; Kullak-Ublick, G A; Fried, M (2006). Gastro-Highlights 2006. Praxis, 95(46):1793-1804.

Mullhaupt, B; Kullak-Ublick, G A; Ambühl, P M; Stocker, R; Renner, E L (2003). Successful use of the Molecular Adsorbent Recirculating System (MARS) in a patient with primary biliary cirrhosis (PBC) and treatment refractory pruritus. Hepatology Research, 25(4):442-446.

Mullhaupt, B; Kullak-Ublick, G A; Ambühl, P; Maggiorini, M; Stocker, R; Kadry, Z; Clavien, P A; Renner, E L (2002). First clinical experience with Molecular Adsorbent Recirculating System (MARS) in six patients with severe acute on chronic liver failure. Liver International, 22 Sup:59-62.

Hagenbuch, N; Reichel, C; Stieger, B; Cattori, V; Fattinger, K E; Landmann, L; Meier, P J; Kullak-Ublick, G A (2001). Effect of phenobarbital on the expression of bile salt and organic anion transporters of rat liver. Journal of Hepatology, 34(6):881-887.

Ismair, M G; Stieger, B; Cattori, V; Hagenbuch, B; Fried, M; Meier, P J; Kullak-Ublick, G A (2001). Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting polypeptides OATP4 and OATP8 of rat and human liver. Gastroenterology, 121(5):1185-1190.

Gao, B; Hagenbuch, B; Kullak-Ublick, G A; Benke, D; Aguzzi, A; Meier, P J (2000). Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. Journal of Pharmacology and Experimental Therapeutics, 249(1):73-79.

Fattinger, K; Roos, Malgorzata; Spiess, A; Vergères, P; Braunschweig, S; Kullak-Ublick, G A; Galeazzi, R L; Follath, F; Schaffner, A; Gasser, T; Meier-Abt, P J (2000). Die "Stiftung für Arzneimittelsicherheit" SAS/CHDM: Update 2000. Schweizerische Ärztezeitung (SÄZ), 81(42):2381-2384.

This list was generated on Mon Jul 24 18:52:30 2017 CEST.